Welcome to our dedicated page for Evoke Pharma news (Ticker: EVOK), a resource for investors and traders seeking the latest updates and insights on Evoke Pharma stock.
Evoke Pharma, Inc. was a specialty pharmaceutical company focused on treatments for gastrointestinal diseases, with emphasis on GIMOTI, a metoclopramide nasal spray for relief of symptoms in adults with acute and recurrent diabetic gastroparesis. Company news has centered on GIMOTI commercialization, specialty pharmacy and GI practice access, FDA Orange Book and USPTO patent developments, product safety information, and periodic operating results.
Evoke became a wholly owned subsidiary of QOL Medical after a completed tender offer and merger, and its common stock ceased trading on Nasdaq. Subsequent company updates reflect that corporate-status transition alongside the historical GIMOTI business.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.